Regulation 40 Amendment of regulation 13
Regulation 13 (supply of investigational medicinal products for the purpose of clinical trials)f1 is amended as follows.
In paragraph (2)(b)(i), after “United Kingdom” insert “except for an MM investigational medicinal product or a POC investigational medicinal product”.
After paragraph (2)(b)(i) insert—
“(ia)an MM investigational medicinal product manufactured or assembled in the United Kingdom, the product has been manufactured or assembled in accordance with the terms of a manufacturing authorisation (MM) or assembled under the exemption in regulation 37;
(ib)a POC investigational medicinal product manufactured or assembled in the United Kingdom, the product has been manufactured or assembled in accordance with the terms of a manufacturing authorisation (POC) or assembled under the exemption in regulation 37;”.
Annotations
Footnotes
- f1
-
Paragraph (2)(b) was substituted by S.I. 2019/775. There are other amendments but none is relevant.